Introgen announces data that INGN 241 Cancer Therapy Inhibits Tumor Angiogenesis By Blocking Production of VEGF (INGN) 5.21 +0.20:Co announces reported data describing a novel mechanism of action by which its mda-7/IL 24 based therapy, INGN 241, inhibits the formation of new blood vessels, called angiogenesis. In the absence of angiogenesis, tumors cannot establish a sufficient supply of oxygen and nutrients causing tumor cell death and inhibition of tumor growth. The co's studies demonstrate that INGN 241 acts as an anti-angiogenic agent to inhibit production of a key mediator of angiogenesis called vascular endothelial growth factor protein. These studies are published in the current issue of Molecular Therapy and were conducted by researchers at Introgen and their collaborators at The University of Texas M. D. Anderson Cancer Center. "The data reported today demonstrate that INGN 241 blocks VEGF gene expression and production of VEGF protein. Because VEGF is such a potent stimulator of tumor angiogenesis, eliminating or reducing the amount of VEGF protein produced by cancer cells may have important therapeutic effects. The multiple anti-cancer activities of INGN 241 make this agent a unique cancer treatment that incorporates several validated therapeutic approaches into a single drug."
Market Data 
Markets 
AI
